The Weekly Roundup: December 8-12

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Abeona Initiates First Commercial Treatment of Zevaskyn for RDEB

The first treatment follows Zevaskyn’s FDA approval as the first autologous, gene-modified cellular sheet designed to address RDEB wounds.

High Allergen Content Detected in North American Hotel Toiletries Compared to Europe

Discover how hotel shampoos, conditioners, and body washes contribute to allergic contact dermatitis, revealing significant regional differences in allergen prevalence.

KT-621 Produces 98% STAT6 Degradation in AD Patients

Kymera Therapeutics reveals promising phase 1b results for KT-621, an oral STAT6 degrader, showing significant effects in moderate to severe atopic dermatitis.

PolarityBio Completes Pivotal Phase 3 Trial of SkinTE for Diabetic Foot Ulcers

PolarityBio advances SkinTE for diabetic foot ulcers, aiming for a breakthrough in chronic wound treatment with promising trial results announced soon.

Transparency Gaps in Prior Authorization Denials and Their Impact on Dermatologic Care

John Barbieri, MD, MBA, outlines how missing reviewer identification, unclear step-therapy requirements, and limited engagement during appeals contribute to delays and inefficiencies.

Celebrating a Year of Growth and Research

Dermatology Times highlights 2025's innovations in dermatology, featuring new therapies, expert insights, and a look ahead to 2026 advancements.

AI at the Bedside: How Automated Solutions are Transforming Vitiligo Management

AI could revolutionize vitiligo management with enhanced diagnostics, automated tracking, and personalized treatment forecasting, improving patient care and outcomes.

Meta-analysis Confirms Benefits of Roflumilast 0.3% Cream for PsO

Discover the efficacy and safety of topical roflumilast 0.3% for psoriasis, highlighting its rapid results and potential for sensitive skin areas.

Celldex Advances Barzolvolimab into Phase 3 for Cold Urticaria and Symptomatic Dermographism

Celldex is launching a phase 3 trial for barzolvolimab, targeting cold urticaria and symptomatic dermographism, offering hope for effective treatment options.

New Perspectives in Chronic Hand Eczema Care

Lakshi Aldredge, MSN, ANP-BC, DCNP, discussed key symptoms of CHE, the function of the JAK-STAT pathway, and key data from the DELTA trials evaluating delgocitinib cream at Horizons.

A Patient–Physician Lens on the Real Burden of CHE

Explore the emotional and physical challenges of chronic hand eczema through a patient's journey and expert insights on empathetic care and innovative treatments.

Journal Digest: December 10, 2025

This review of the latest dermatologic studies includes a review on JAK-induced acne, a case series of atypical pediatric-onset Behçet's Disease, research on drug survival in AD, and more.

When Hives Do Not Quit: A Practical Update on Chronic Spontaneous Urticaria

Explore the latest advancements in chronic spontaneous urticaria (CSU) therapies, including innovative treatments and patient-centered management strategies.

Enzymatic Debridement Reduces Pigment Load by Over 90% in Injuries

MediWound reveals clinical data showing NexoBrid significantly reduces pigmentation in traumatic tattoos from abrasions and blast injuries.

Access to Full PT Panels Vital for Patient Care

Comprehensive patch testing is vital for accurately diagnosing various forms of dermatitis, improving patient care, and addressing public health challenges.

Impaired HRQoL and High Psychological Comorbidity Observed in Japanese Vitiligo Patients

A nationwide survey in Japan reveals significant health-related quality of life and psychological challenges faced by patients with vitiligo, highlighting the need for better mental health support.

Delgocitinib Offers Targeted Relief for the Painful Burden of Chronic Hand Eczema

Omar Noor, MD, discusses how pain and functional impairment define CHE and reviews why topical delgocitinib provides early symptomatic relief and improved adherence.

Site-Specific MED Variability Guides 308-nm Excimer Laser Dosing

Discover how anatomical variations impact the minimal erythema dose in 308-nm excimer laser therapy for vitiligo in Asian patients.

Transformative Advances This Year and Beyond

This year marked a transformative period, defined by a series of groundbreaking FDA approvals that expanded treatment options across a wide range of skin conditions

Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population

A new global study reveals hidradenitis suppurativa affects 1 in every 100 people, highlighting the need for increased awareness and improved health care strategies.

FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol

FDA proposes adding bemotrizinol to sunscreen ingredients, enhancing UV regulations and protection options for consumers for the first time since 1999.

Phase 3b Study Confirms Ligelizumab’s Consistent CSU Control

Explore the long-term efficacy and safety of ligelizumab for CSU, highlighting self-administration success and significant symptom control.

The SkinCARE Questionnaire: Assessing the Psychological Dimensions of Skin Health Beyond Disease

Discover how the SkinCARE Questionnaire can measure the emotional impact of everyday skin health, enhancing understanding of skin-related wellbeing in healthy individuals.

Mohs Micrographic Surgery in High-Profile Patients: A Call for Expanding Access to Skin Cancer Care

President Biden's Mohs surgery highlights the need for equitable access to this effective skin cancer treatment, emphasizing its benefits and ongoing disparities.

"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions

Explore the emerging concept of PDE4 inhibitor-responsive dermatoses, offering innovative nonsteroidal treatments for chronic inflammatory skin conditions.

JAK Inhibitors Show Comparable Safety to TNF Antagonists

A meta-analysis of over 800,000 patients shows JAK inhibitors are generally as safe as TNF antagonists for various purposes.

Emerging Topical Alternatives to Hydroquinone in Melasma Management

An updated review offers effective alternatives to hydroquinone for melasma treatment, including thiamidol and natural agents, with improved safety profiles.